AnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic Sclerosis
First-in-class, peripheral-acting serotonin receptor antagonist being developed as an anti-fibrotic treatment for systemic sclerosis
Lund, Sweden, 5 Feb 2024: AnaMar, a clinical-stage biotech company developing first in class anti-fibrotic 5-HT2B receptor antagonists, announces that the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have granted orphan drug designation (ODD) to its lead clinical candidate, AM1476 for the treatment of systemic sclerosis (SSc).
